BioVex is a biotechnology company focused on the development and commercialisation of biological treatments for cancer and the prevention of infectious disease. The company’s lead cancer programme, OncoVEXGM-CSF, is a first in class oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed.
BioVex is headquartered in Woburn, Massachusetts, and also has research facilities near Oxford in the UK.